2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Vogel M, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Florendo E, Karlin L, Weisel K. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. The Lancet Haematology 2025, 12: e45-e56. PMID: 39756844, DOI: 10.1016/s2352-3026(24)00320-x.Peer-Reviewed Original ResearchConceptsLenalidomide-refractory multiple myelomaStandard of careVisual analogue scaleMultiple myelomaGlobal health statusPatient-reported outcomesCiltacabtagene autoleucelIntention-to-treat populationLenalidomide-refractory diseaseProgression-free survivalECOG performance statusPhase 3 trialEORTC global health statusWorsening of symptomsClinically meaningful improvementsEuropean Organisation for ResearchEQ-5D-5L visual analogue scaleCilta-celEuroQol 5-Dimension 5-LevelOpen-labelImmunomodulatory drugsMedian agePerformance statusSecondary endpointsClinical efficacy
2007
Transforming Growth Factor- Signaling in Normal and Malignant Hematopoiesis
Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, Pahanish P, Verma A. Transforming Growth Factor- Signaling in Normal and Malignant Hematopoiesis. Journal Of Interferon & Cytokine Research 2007, 27: 543-552. PMID: 17651015, DOI: 10.1089/jir.2007.0009.Peer-Reviewed Original ResearchConceptsIntracellular TGF-beta signalingFuture therapeutic interventionsImportant physiologic regulatorTGF-beta receptorsTGF-beta signalingPremalignant stateLymphoid neoplasmsSmall molecule inhibitorsMyeloid cellsTGF receptorTherapeutic interventionsTumor growthHematopoietic stem cellsPhysiologic regulatorTumor microenvironmentGrowth factorGrowth factor signalingMolecule inhibitorsQuiescent hematopoietic stem cellsStem cellsFactor signalingReceptorsCell growthLate progenitorsMalignant hematopoiesis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply